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ABSTRACT
Introduction: Inappropriate antibiotic use in
COVID-19 is often due to treatment of presumed bacterial coinfection. Predictive factors
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to distinguish COVID-19 from COVID-19 with
bacterial coinfection or bloodstream infection
are limited.
Methods: We conducted a retrospective cohort
study of 595 COVID-19 patients admitted
between March 8, 2020, and April 4, 2020, to
describe factors associated with a bacterial
bloodstream coinfection (BSI). The primary
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outcome was any characteristic associated with
BSI in COVID-19, with secondary outcomes
including 30-day mortality and days of antibiotic therapy (DOT) by antibiotic consumption
(DOT/1000 patient-days). Variables of interest
were compared between true BSI (n = 25) and all
other COVID-19 cases (n = 570). A secondary
comparison was performed between positive
blood cultures with true BSI (n = 25) and contaminants (n = 33) on antibiotic use.
Results: Fever ([ 38 °C) (as a COVID-19 symptom) was not different between true BSI (n = 25)
and all other COVID-19 patients (n = 570)
(p = 0.93), although it was different as a reason
for emergency department (ED) admission
(p = 0.01). Neurological symptoms (ED reason
or COVID-19 symptom) were significantly
higher in the true BSI group (p \ 0.01, p \ 0.01)
and were independently associated with true
BSI (ED reason: OR = 3.27, p \ 0.01; COVID-19
symptom: OR = 2.69, p = 0.03) on multivariate
logistic regression. High (15–19.9 9 109/L)
white blood cell (WBC) count at admission was
also higher in the true BSI group (p \ 0.01) and
was independently associated with true BSI
(OR = 2.56, p = 0.06) though was not statistically significant. Thirty-day mortality was
higher among true BSI (p \ 0.01). Antibiotic
consumption (DOT/1000 patient-days) between
true BSI and contaminants was not different
(p = 0.34). True bloodstream coinfection was
4.2% (25/595) over the 28-day period.
Conclusion: True BSI in COVID-19 was associated with neurological symptoms and nonsignificant higher WBC, and led to overall
higher 30-day mortality and worse patient
outcomes.
Keywords: Bacterial coinfection; Blood culture;
Bloodstream infection; COVID-19; Risk factors
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Key Summary Points
Why carry out this study?
COVID-19 is persisting throughout the
world with the spread of new variants.
Patients will continue to be infected with
COVID-19, and a portion of those infected
will also have positive blood cultures
either as true bloodstream infections or as
contaminants.
This manuscript seeks to provide evidence
to differentiate patients with true
bloodstream coinfection versus COVID-19
alone and describe their outcomes. It also
details antibiotic use between those with
true bloodstream infections and
contaminant positive blood cultures.
What was learned from the study?
True bacterial bloodstream coinfection in
COVID-19 was associated with
neurological symptoms and higher white
blood cell (WBC) count, and led to overall
worse patient outcomes.
These data can help confirm previous data
regarding bacterial bloodstream
coinfection in COVID-19 and provide
helpful diagnostic factors such as white
blood cell count or presence of
neurological symptoms to aid in
differentiating true bloodstream
coinfection vs. COVID-19 alone.

INTRODUCTION
Coronavirus disease 2019 (COVID-19) has
remained a distinct cause of morbidity and
mortality since the World Health Organization
(WHO) declared the novel coronavirus a pandemic on March 11, 2020 [1]. Severe COVID-19
is an acute culmination of the disease that can
send patients to the hospital with sequelae and
symptoms that seem similar to community-
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acquired bacterial pneumonia that would warrant antibiotics [2–6]. Meanwhile, antibiotic
overuse has led to broad antibiotic resistance,
contributing to another persistent pandemic of
difficult-to-treat bacterial infections [7–10].
Given that the presenting symptoms of COVID19 and bacterial coinfection are similar, distinguishing between them is difficult. Understanding the risk of coinfection in COVID-19,
awareness of the risks of inappropriate antibiotics, and identifying any factors that can help
differentiate bacterial coinfection and the need
for antibiotics are keys to controlling both
pandemics.
The risk of bacterial coinfections with
COVID-19 were described in a few early studies.
In brief, rates of bacterial coinfection as a whole
or with positive blood culture varied between
3.6 and 15% in COVID-19 patients during the
initial phase of the pandemic [11–20]. This level
indicates relatively low risk for bacterial coinfection. However, many studies excluded or did
not report contaminants in patients, limiting
analysis [11–14]. Furthermore, there were few
recommendations or predictive characteristics
suggested to differentiate true bacterial coinfection from contaminants besides the lack of
positive cultures [20]. Without additional laboratory or symptomatic factors to differentiate
bacterial bloodstream coinfection in COVID-19,
prognostication of patients with COVID-19 will
remain challenging with regard to withholding
antibiotics. Antibiotics should be withheld in
patients with contaminant-positive blood cultures, and data on antibiotic use can corroborate whether this occurred in COVID-19
patients with true BSI versus contaminants.
Blood cultures containing contaminant
organism(s) may falsely raise the alarm and
appear as a true infection in the setting of
COVID-19. Contaminant blood cultures are
most often only positive in a small fraction of
drawn blood culture specimens, and these are
commonly skin contaminants such as coagulase-negative staphylococci, micrococci, and
Corynebacterium species, among others [21].
Furthermore, infection control and good
hygiene practices may have been neglected
during the early pandemic. Higher patient
caseloads, overflowing emergency departments

1283

(ED), and poor patient isolation may have led to
poor hand hygiene and use of standard precautions when drawing blood cultures that
could have led to increased contamination
[18, 22]. There have also been studies showing
increases
in
central-line-associated
BSI
(CLABSI), catheter-associated urinary tract
infections (CAUTI), and ventilator-associated
events (VAE) during the first year of the pandemic, linking specific increases in BSI to a
definitive source [23–25]. Regarding factors that
may predict coinfection, classically, the presence of fever is one factor associated with bacterial infections that would warrant antibiotic
treatment; however, fever is also common in
COVID-19 [26, 27]. Another possible factor that
may help in diagnostic differentiation is white
blood cell (WBC) count, as lower WBC counts
have been associated with COVID-19 infection,
and higher WBC counts may indicate bacterial
infection [28]. Other symptoms or characteristics may help differentiate bacterial infection.
Emphasizing the extent of inappropriate
antibiotic prescribing, in a large Italian multicenter study of 13,932 COVID-19 patients, only
44% were prescribed antibiotics appropriately,
and 34.2% of patients received inappropriately
prescribed antibiotics. Cough, fever, shortness
of breath, and the absence of comorbidities
were found to be independently associated with
inappropriate antibiotic prescription [29]. It is
important to identify patient factors associated
with true coinfection in COVID-19 patients in
order to reduce inappropriate antibiotic use.
Given the clinical questions presented above
and COVID-19 persistence with variants
throughout the world, we aimed to utilize our
data to help answer other remaining clinical
questions on bacterial coinfection and antibiotic stewardship. We sought to determine predictive factors associated with true BSI against
other COVID-19 patients with negative, not
drawn, and/or contaminant blood cultures. This
study also aims to provide the overall proportion of true BSI among COVID-19 patients at
the Detroit Medical Center in the first wave of
2020, and investigates whether there is a difference in antimicrobial use between COVID-19
patients with true BSI and those with contaminant blood cultures.
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METHODS
This was a retrospective, observational, cohort
study of COVID-19 patients admitted between
March 8, 2020, and April 4, 2020, at a single
medical system alliance of four hospitals in
Detroit, Michigan. Patient demographics,
patient history, disease severity (APACHE
[Acute Physiology and Chronic Health Evaluation] II score), reason for ED admission, COVID19 symptoms, microbiology, treatments, and
outcomes were collected from the electronic
medical record. Patients were included if they
were C 18 years old, COVID-19 polymerase
chain reaction (PCR)-positive, and admitted
between March 8 and April 4, 2020. Exclusion
criteria included patients who were prisoners,
those who were pregnant, or patients hospitalized outside of the targeted medical system.
Patients were initially separated into those
with a positive blood culture for any organism
and those without positive blood cultures,
which included patients with negative blood
cultures and those without any blood culture
drawn. Patients with positive blood cultures
were further separated into cases with true BSI
and those identified as contaminants. The main
comparison consisted of patients with true BSI
and COVID-19 and those without true BSI with
COVID-19. The primary outcome was predictive
variables associated with true BSI. Secondary
outcomes included all-cause 30-day mortality
and antibiotic consumption evaluated between
true BSI and contaminant blood cultures. Targeted predictive factors for true BSI association
included fever ([ 38 °C) (either as a reason for
ED admission or as a general COVID-19 symptom) and WBC count at admission, separated as
a categorical variable into low (1–2.9 9 109/L),
normal (3–14.9 9 109/L), high (15–19.9 9 109/
L), and very high (20–39.9 9 109/L) strata.
COVID-19 symptoms and reasons for ED
admission were both collected using the same
list of potential answer choices (none, cough,
shortness of breath, fever—temp. [ 38.0 °C,
sore throat, myalgia, headache, nausea, vomiting, abdominal pain, diarrhea, chest pain, neurological, anosmia, generalized weakness,

other), in which multiple choices could be
selected.
Definitions
True BSI was defined as any pathogenic organism (Staphylococcus aureus, Candida species,
Gram-negative organisms, etc.) in one blood
culture specimen, or any organism (pathogen or
commensal) in two blood culture specimens.
Contaminant blood culture was defined as only
one blood culture specimen positive for a
common contaminant organism (coagulasenegative Staphylococcus [CONS], micrococcus, or
non-speciated Gram-positive cocci) or when
defined as such in clinical diagnostic notes.
Antibiotic consumption was defined as antibiotic days of therapy (DOT) per 1000 patientdays analyzed for those with positive blood
cultures (true BSI and contaminants). Antibiotic
DOT are the number of days a single antibiotic
was given to a patient, and these accumulate
per antibiotic. Immunocompromised status was
defined according to APACHE II criteria as
chemotherapy, radiation, long-term or highdose steroids, advanced leukemia, lymphoma,
or autoimmune deficiency syndrome (AIDS)
[30]. Thirty-day mortality was measured from
the date of admission.
Statistical Analysis
Nominal variables were compared using the
Pearson Chi-squared test or Fisher’s exact test,
as appropriate. Ordinal and continuous variables were analyzed using the Mann–Whitney
U-test and Student’s t-test for nonparametric
and parametric data, respectively. Statistical
significance between data was set at p-values
of\ 0.05. Multivariate logistic regression was
utilized to determine whether a statistically
significant factor was an independent predictor
for true BSI. The regression model was performed stepwise with significance criteria of
entry = 0.05 and removal = 0.1. Variables were
chosen based on likelihood of affecting the
predictive factor. For WBC, four variables were
chosen: age, APACHE II score, COVID-19-associated med: glucocorticoids, and WBC count
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‘‘high’’ (15–19.9). For neurological symptoms as
a reason for ED admission and as a general
COVID-19 symptom, five variables were chosen
in addition to neurological symptom: patient
history of dementia, history of moderate to
severe liver disease, chronic dialysis, APACHE II
score, and COVID-19-associated med: glucocorticoids. Odds ratios (ORs) were used in the
final model to report the factor’s associated
likelihood for true BSI. Statistics were calculated
using IBM SPSS Statistics, version 28.0 (IBM
Corp., Armonk, NY, USA) using code that is
available in the Supplemental Material.
Patient clinical data were collected and
managed using the Research Electronic Data
Capture (REDCap) tool hosted at Wayne State
University [31]. The Wayne State Institutional
Review Board (IRB) with Detroit Medical Center
research authorization approved the study
design and reporting, and waived the requirement for patient consent. Data are available on
request to m.rybak@wayne.edu given patient
confidentiality regulations from a limited data
set under the Health Insurance Portability and
Accountability Act (HIPAA).

RESULTS
There were 848 cases recorded in the COVID-19
database among two medical systems. Upon
targeting a single medical system, there were
187 COVID-19 patients excluded from analysis,
and 66 cases were excluded due to an admission
date outside of the target of March 8, 2020, to
April 4, 2020. This left 595 cases of patients with
COVID-19, split into 537 cases of those without
positive blood cultures and 58 cases with positive blood cultures. Positive blood culture cases
were secondarily split into true BSI (n = 25) and
contaminants (n = 33) (Fig. 1). Table 1 describes
patient characteristics of those with (n = 25)
and without true BSI (n = 570), which were
found to be relatively similar. It shows that
patients at the Detroit Medical Center were
older, more often male, with a race breakdown
that mirrored Detroit’s census data [32]. Nearly
50% of patients were obese, which is a higher
proportion than census data, and is consistent
with obesity as a strong risk factor for severe
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Fig. 1 CONSORT [Consolidated Standards Of Reporting Trials] diagram for inclusion

COVID-19 given all patients were hospitalized
and had severe COVID-19 [33, 34]. Also, while
hospitalization in the past 30 days was a significant risk factor associated with true BSI and
COVID-19, only 3.4% of all patients had been
hospitalized for C 48 h in the past 90 days,
suggesting broad community spread among
non-hospitalized patients. Statistically significant differences between the two groups of
COVID-19 patients included APACHE II score,
immunocompromised condition, prior hospitalization in the past 30 days, and prior hospitalization for C 48 h in the past 90 days, which
were all more common/higher in the true BSI
group.
Infection characteristics and outcomes in
Table 2 revealed some statistically significant
differences, including higher intensive care unit
(ICU) admission (76% vs. 36%, p \ 0.01),
mechanical ventilation (64% vs. 33%, p \ 0.01),
and vasopressor use (36% vs. 9.5%, p \ 0.01),
among patients with true BSI. Important to note
as well for the timing of blood cultures, the
median time to drawn blood culture among
positive blood cultures since admission was
0 days, with an interquartile range (IQR) of
2.4 days, and 76% of blood cultures that were
positive were drawn within 1 day of admission.

Infect Dis Ther (2022) 11:1281–1296

1286

Table 1 Patient characteristics
Characteristic

Table 1 continued

COVID-19
patients
(n = 570)

COVID-19
patients with
true BSI
(N = 25)

Age, years; mean, (SD)

63.7 (14.6)

63.8 (17.8)

0.98

Sex, male

295 (52)

14 (56)

0.84

African-American

448 (79)

19 (76)

0.80

Caucasian

33 (5.8)

2 (8.0)

0.65

Multiple/other

23 (4.0)

1 (4.0)

1.0

Unknown

66 (12)

3 (12)

1.0

BMI, kg/m ; median,
(IQR)

30.6 (11.1)

31.7 (21.6)

0.40

[n = 492]

[n = 22]

APACHE II; mean,
(SD)

15.5 (9.8)

25.3 (9.1)

Charlson comorbidity
index; mean, (SD)

3.8 (2.5)

3.7 (2.4)

0.96

Obesity (BMI C 30)

263 (46)

12 (48)

0.86

MI

21 (3.7)

2 (8.0)

0.25

CHF

74 (13)

5 (20)

0.36

Dementia

35 (6.1)

3 (12)

0.21

Diabetes mellitus

212 (37)

14 (56)

0.06

Chronic obstructive
pulmonary disease

92 (16)

3 (12)

0.78

Asthma

57 (10)

3 (12)

0.73

HIV

7 (1.2)

1 (4.0)

0.29

PWID

3 (0.5)

0 (0)

1.0

Tumor, any

20 (3.5)

2 (8.0)

0.24

Immunocompromised
(APACHE-deﬁned)

4 (0.7)

2 (8.0)

0.02

None

82 (14)

1 (4.0)

0.23

p value

Demographics

COVID-19
patients
(n = 570)

COVID-19
patients with
true BSI
(N = 25)

p value

Prior surgery in
30 days preceding
encounter

4 (0.7)

0

1.0

Prior hosp in past
30 days

72 (13)

8 (32)

0.02

Prior hosp C 48 h
in 90 days
preceding
encounter

16 (2.8)

4 (16)

\ 0.01

Prior infection in
365 days preceding
encounter

17 (3.0)

0

1.0

Prior abx C 48 h
w/in past year

21 (3.7)

1 (4.0)

1.0

Risk factors

Race

2

Characteristic

\ 0.01

Comorbidities

Abx antibiotics, SD standard deviation, BMI body mass index,
IQR interquartile range, hosp hospitalization, MI myocardial
infarction, CHF chronic heart failure, PWID people who inject
drugs

This extends to the true BSI group, with a
median (IQR) time to drawn blood culture of 0
(6.5) days and 64% of blood cultures drawn
within 1 day of admission (Table 2).
Reasons for presenting to the ED, overall
COVID-19 symptoms, and COVID-19-associated medications had certain differences
between non-BSI (n = 570) and BSI (n = 25)
cohorts. Cough (47% vs. 20%, p \ 0.01) and
fever (36% vs. 12%, p = 0.01) as reasons for ED
presentation were all higher in the non-BSI
COVID-19 group. However, neither cough
(p = 0.07) nor fever (p = 0.93) as a COVID-19
symptom was statistically different between
groups. Neurological symptoms did show significant differences as a reason for ED admission
(40% vs. 12%, p \ 0.01) and as a COVID-19
symptom (32% vs. 11%, p \ 0.01), both higher
in the true BSI group. Higher WBC count as an
ordinal measure was associated with true BSI
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Table 2 Infection characteristics
Characteristic

COVID-19
patients
(n = 570)

Table 2 continued
COVID-19
patients with
true BSI
(N = 25)

p value

Infection characteristics

Characteristic

COVID-19
patients
(n = 570)

COVID-19
patients with
true BSI
(N = 25)

p value

0 (0)

1 (4.0)

0.04

Hydroxychloroquine 442 (78)

21 (84)

0.45

Chloroquine

0

0

–

COVID-19associated meds

Reason for
presenting to ED

Lopinavir/ritonavir

SOB

320 (56)

13 (52)

0.68

Cough

269 (47)

5 (20)

\ 0.01

Fever ([ 38 °C) 206 (36)

3 (12)

0.01

Remdesivir

0

0

–

Sore throat

18 (3.2)

0

1.0

Glucocorticoids

179 (31)

13 (52)

0.03

Myalgia

57 (10)

1 (4.0)

0.50

Tocilizumab

2 (0.4)

2 (8.0)

0.01

Abdominal pain

22 (3.9)

2 (8.0)

0.27

0

0

-

Diarrhea

67 (12)

1 (4.0)

0.34

IL-1 or other IL-6
inhibitor

Neurological

70 (12)

10 (40)

\ 0.01

0 (6.5)

0.10

SOB

387 (68)

18 (72)

0.67

Cough

395 (69)

13 (52)

0.07

Fever ([ 38 °C) 324 (57)

14 (56)

0.93

Sore throat

35 (6.1)

2 (8.0)

0.66

Myalgia

115 (20)

2 (8.0)

0.20

Abdominal pain

28 (4.9)

2 (8.0)

0.36

Diarrhea

118 (21)

2 (8.0)

0.12

Neurological

65 (11)

8 (32)

\ 0.01

None

8 (1.4)

1 (4.0)

0.32

COVID-19
symptoms

WBC count
(109/L)

0.01

1–2.9

34 (6.0)

0

0.39

3–14.9

453 (80)

18 (72)

0.37

15–19.9

45 (7.9)

7 (28)

20–39.9

18 (3.2)

0

\ 0.01
1.0

Time to blood culture 0 (3.3)
[n = 33]
collection, days;
median (IQR)
Mechanical
ventilation

188 (33)

16 (64)

\ 0.01

ICU admission

203 (36)

19 (76)

\ 0.01

Vasopressor use

54 (9.5)

9 (36)

\ 0.01

Length of stay, days; 8.0 (9.0)
median (IQR)

17 (27)

\ 0.01

Readmission, 30-day 9 (2.2)

0

Mortality, 30-day

17 (68)

Outcomes

190 (34)

1.0
\ 0.01

ED emergency department, SOB shortness of breath, WBC white
blood cell, Meds medications, ICU intensive care unit, IL
interleukin

(p = 0.01) and high WBC (15–19.9 109/L) category was significantly higher in the true BSI
group (28% vs. 7.9%, p \ 0.01). COVID-19-associated medications such as lopinavir/ritonavir
(p = 0.04), glucocorticoids (p = 0.03), and tocilizumab (p = 0.01) were all used statistically
more often in the true BSI cohort. Secondary
outcome of 30-day mortality in the comparison
was statistically higher in the true BSI group
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Table 3 Infection and treatment among COVID-19positive blood cultures (n = 58)
Characteristic

Contaminant True
p value
(n = 33)
BSI
(n = 25)

Pathogen
Candida

0

3 (12)

0.08

Coagulase-negative
Staph

27 (82)

9 (36)

\ 0.01

Enterobacterales

0

2 (8.0)

0.18

Enterococcus

0

4 (16)

0.03

Staphylococcus
aureus

0

5 (20)

0.01

Pseudomonadales

0

0

–

28 (85)

20 (80)

0.73

0

6 (24)

Antibiotic used, any
Antifungals

Anti-MRSA agents 18 (55)

\ 0.01

18 (72)

0.18

Vancomycin

18 (55)

17 (68)

0.30

Linezolid,
daptomycin,
ceftaroline

3 (9)

4 (16)

0.45

Beta-lactams

27 (82)

20 (80)

1.0

Penicillins

1 (3)

2 (8)

0.57

First-generation
cephalosporins

1 (3)

4 (16)

0.15

Third-generation
cephalosporins

21 (64)

12 (48)

0.23

Fourth-generation 14 (42)
cephalosporins

16 (64)

0.10

Carbapenems

3 (9.1)

6 (24)

0.15

Fluoroquinolones

1 (3)

1 (4)

1.0

Macrolides

7 (21)

12 (48)

0.03

Tetracyclines

17 (52)

9 (36)

0.24

Table 3 continued
Characteristic

Contaminant True
p value
(n = 33)
BSI
(n = 25)

Antibiotic treatment
Antibiotics per
patient; median
(IQR)

2.0 (2.0)

4.0 (3.0) 0.07

Abx DOT per
patient, days;
median

8.0 (12.5)

10
(13.5)

Abx DOT per
antibiotic, days;
median

3.0 (3.4)

2.7 (3.3) 0.45

Abx Consumption,
DOT per 1000
patient-days;
median

800 (1339)

652
(593)

0.69

0.34

MRSA methicillin-resistant Staphylococcus aureus, Abx
antibiotics, DOT days of therapy
(68% vs. 34%, p \ 0.01). Other outcomes such
as length of stay (LOS) were also higher in the
true BSI group (17 vs. 8.0 days, p \ 0.01). and
30-day readmission was not significantly different between cohorts (p = 1.0).
A secondary analysis between contaminant
blood cultures (n = 33) and true bloodstream
infection (n = 25) described antibiotic and
organism characteristics between groups
(Table 3). Coagulase-negative staphylococci
were more commonly associated with contaminants (82% vs. 36%, p \ 0.01) compared to true
BSI, while Staphylococcus aureus (20% vs. 0%,
p \ 0.01) and Enterococcus species (16% vs. 0%,
p = 0.03) were associated with true BSI. There
was no difference in contaminant (85%) or true
BSI (80%) receiving any antibiotic (p = 0.73).
There were also no statistically significant differences between the number of antibiotics
used per patient (p = 0.07), antibiotic DOT per
patient (p = 0.69), DOT per antibiotic used
(p = 0.45), or antibiotic consumption as a whole
(DOT/1000 patient-days) between contaminant
or true BSI groups (800 vs. 652, p = 0.34).
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Table 4 Multivariate logistic regression—WBC as a factor
for true BSI
Variable

Adjusted odds
ratio
(95% CI)

p value

WBC Count ‘ high’’
(15–19.9 9 109/L)

2.56
(0.950–6.88)

0.06

APACHE II score

1.07
(1.03–1.11)

\ 0.01

(Intercept)

0.010

\ 0.01

Stepwise logistic regression had entry at signiﬁcance of 0.05
and removal at signiﬁcance of 0.1
Four variables were included in the stepwise regression
analysis: age, APACHE II score, COVID-19-associated
med: glucocorticoids, and WBC count ‘ high’’ (15–19.9).
Age was removed in step 1 at 0.23 signiﬁcance, and
COVID-19-associated med: glucocorticoids was removed
in step 2 at 0.18 signiﬁcance

Multivariate logistic regression was performed for the high WBC (15–19.9 9 109/L)
category and neurological symptoms as a reason
for ED admission and as a COVID-19 symptom
as possible independent predictors for true BSI
(Tables 4 and 5). The regression model was
performed stepwise with significance criteria of
entry = 0.05 and removal = 0.1. Two variables
of APACHE II score and the predictive factor
remained in each regression model. High WBC
had an adjusted OR of 2.56 (95% CI:

0.950–6.88) to predict true BSI; neurological
symptoms as a reason for ED admission and as a
COVID-19 symptom had adjusted ORs of 3.27
(95% CI: 1.36–7.87) and 2.69 (95% CI:
1.08–6.69), respectively.
In total, there were 595 cases of patients with
COVID-19 and 58 cases with a possible bloodstream coinfection, for a proportion of possible
BSI coinfection of 9.7%. After removing contaminant blood cultures, there were 25 cases of
true BSI with COVID-19, for a proportion of
4.2% true bloodstream coinfection with
COVID-19 at this medical system in Detroit
over a 28-day period.

DISCUSSION
The analysis between COVID-19 non-BSI
patients and those with COVID-19 and true BSI
made several notable associations. Firstly, in our
analysis, patients with true BSI and COVID-19
were more likely to have a higher APACHE II
score, be immunocompromised, have prior
hospitalization in the past 30 days, and have a
prior hospitalization for C 48 h in the past
90 days. These factors make plausible physiological sense for an increased risk of developing
BSI given that these affect the immune system
or indicate high contact with healthcare systems. True BSI can also cause a more septic and
severe presentation, which is consistent with
the higher APACHE II score. The lack of other
differences regarding age, demographics,

Table 5 Multivariate logistic regression—neurological symptoms as a factor for true BSI
Variable

Adjusted odds ratio
(95% CI)

p value

Variable

Adjusted odds ratio
(95% CI)

Reason for presenting to ED

3.27 (1.36–7.87)

\ 0.01

COVID-19 symptom

2.69 (1.08–6.69)

0.03

- neurological

p value

- neurological

APACHE II score

1.07 (1.03–1.11)

\ 0.01

APACHE II score

1.07 (1.04–1.11)

\ 0.01

(Intercept)

0.009

\ 0.01

(Intercept)

0.009

\ 0.01

Stepwise logistic regression had entry at signiﬁcance of 0.05 and removal at signiﬁcance of 0.1. Each regression included ﬁve
variables in the stepwise regression analysis in addition to neurological symptom (ED reason or overall COVID-19
symptom): patient history—dementia, patient history—moderate to severe liver disease, chronic dialysis, APACHE II score,
and COVID-19-associated med: glucocorticoids. Chronic dialysis, dementia, liver disease, and COVID-19-associated med:
glucocorticoids were removed in steps 1–4, respectively, due to signiﬁcance [ 0.1
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comorbid conditions, and other classical risk
factors (shown in Table 1) is notable given that
BSI would be assumed to generally affect a more
severely ill patient at hospital presentation. The
timing of patient condition severity near
admission is also supported by the fact that 76%
of positive blood cultures were drawn within
1 day of admission. However, the presence of
true BSI along with COVID-19 does suggest
poorer outcomes, as ICU admission, LOS,
mechanical ventilation, vasopressor use, and
mortality were all higher in the true BSI group.
These data support the notion that true BSI in
the setting of COVID-19 is indeed more severe
than COVID-19 alone, which broadly agrees
with the results of a similar study conducted on
secondary bloodstream infections in COVID-19
[35].
Other potential differences between the
groups include COVID-19 symptom characteristics. These can be used to help identify factors
that may distinguish BSI patients from those
with COVID-19 disease alone early on in hospitalization. Shortness of breath (SOB) was the
most common reason for admission to the ED,
at 56% of patients. The most frequent COVID19 symptoms in general were SOB, cough, and
fever ([ 38 °C), at 50–70% of all patients, with
no significant difference by group (Table 2).
These frequencies mirror other studies and data
on COVID-19 symptom prevalence over broad
swaths of patients that show similar top
COVID-19 symptoms of SOB, cough, and fever
[6, 36, 37]. It is also notable that fever, as a
potential distinguishing factor, was not significantly different between COVID-19 BSI and
non-BSI groups. Fever ([ 38 °C), while significant as a reason for ED admission, which may
be associated more with a patient’s initial presentation, was nonsignificant as any COVID-19
symptom, including symptoms during the
patient’s hospital stay as well. The discordant
association between the groups suggests that
fever is not changed by coinfection in the setting of COVID-19, and other factors may lead a
patient to present to the ED if true BSI is a
component (Table 2). This may also help
explain why cough as a reason for presenting to
the ED was significantly lower in the true BSI
group as well, but also not significantly different
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as a COVID-19 symptom. Therefore, one can
infer that neither fever nor cough is a good
marker for bacterial coinfection in the setting of
COVID-19.
While reasons for presenting to the ED were
somewhat similar across the BSI and non-BSI
groups (Table 2), notably neurological symptoms occurred more often (40% vs. 12%,
p \ 0.01) in true BSI. This difference persisted
into overall COVID-19 neurological symptoms
(32% vs. 11%, p \ 0.01) as well. Neurological
symptoms in the context of the potential
choices available as a reason for ED admission
or COVID-19 symptoms suggest potential presentations including altered mental status, seizures, or any impaired form of cognition. It is
notable that the significant association of neurological symptoms continued through multivariate logistic regression analysis, which
attempted to account for confounding variables
such as patient history of dementia, liver disease, dialysis, and glucocorticoids (Table 5).
Neurological symptoms were near three times
as likely to be associated with true BSI and
COVID-19 and over three times as likely to be
associated with true BSI if neurological symptoms were the reason for ED admission
(Table 5). A possible explanation for neurological symptom significance is that neurological
symptoms could have been due to sepsis-associated encephalopathy from true BSI. Sepsis
often occurs with acute brain dysfunction, and
severity can range from mild delirium to deep
coma. It has also been thought to be an early
indicator of bacterial infection in the body and
could present before classic septic symptoms
[38, 39]. This also can lead to a decreased Glasgow Coma Score (GCS), which is an important
component of the APACHE II score, and which
was also found to be significantly associated
with true BSI. However, adjustment for APACHE
II score still found neurological symptoms
themselves significantly associated with true
BSI. The sepsis-associated encephalopathy
explanation may also explain why the difference was slightly starker as a reason for ED
admission compared to COVID-19 symptoms
given the timing; however, further research in
this area is warranted.
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Another factor that may distinguish bacterial
coinfection is WBC. A high WBC was more
prevalent in COVID-19 patients with true BSI
compared to the discordant results with fever,
which suggests that WBC is a better marker for
bacterial coinfection than fever (Table 2). This
may be especially true since COVID-19 patients
often have lower WBC counts [5]. The result was
supported by multivariate logistic regression
analysis to account for confounders, which
showed that the high WBC category was almost
three times as likely to have true BSI as the nonBSI COVID-19, although this result on adjustment was found nonsignificant (p = 0.06)
(Table 4). These data and regression show that
WBC count at admission when COVID-19 is
suspected, especially at higher counts between
15 and 19.9 9 109/L, may be more likely to
suggest bacterial coinfection than lower WBC
counts.
The secondary analysis of positive blood
cultures between contaminants and true BSI
illustrated a pathogen breakdown that is consistent with known evidence. Blood culture
contaminants are more commonly coagulasenegative staphylococci as a skin contaminant,
and Staphylococcus aureus and Gram-negative
pathogens should always be treated as true
infection [21]. However, an unexpected result
from the study was that antibiotic use, antimicrobials used, and overall antibiotic consumption (DOT per 1000 patient-days) were not
significantly different between true BSI and
contaminants (Table 3). While patients with
contaminant blood cultures may receive an
initial antibiotic regimen until culture speciation and clinician evaluation, antibiotics should
be promptly discontinued once it has been
identified that there exists no other indication
for antibiotics. The data shown here illustrate
that antimicrobials were continued even in
patients with contaminants for around 3 days
for each antimicrobial among COVID-19
patients. This suggests that patients were continued on antibiotics possibly due to concern
for coinfection even when no coinfection was
present. This highlights the need to identify
contaminant cultures early, and provide
improved education around discontinuing
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antibiotics in the setting of only contamination
if no other indication exists.
While possible bloodstream rates were 9.7%
for all positive blood cultures, which is higher
than that in other studies, removing contaminants led to a true bloodstream coinfection rate
of 4.2% among COVID-19 patients. This rate of
true coinfection generally mirrors that in other
studies, with rates of 7.2%, 6.1%, and 3.6%, and
bacteremia rates of 6% and 1.6% among
COVID-19 patients [6, 11, 15, 40, 41]. However,
the initial high rate of bloodstream contaminants suggests that this region may have suffered from high amounts of contamination in
the early stages of the pandemic. From the data,
over half of the positive blood cultures in
COVID-19 during this period were contaminant
blood cultures. A study analyzing CLABSIs and
blood culture contamination rates at this
healthcare system also agree that the blood
culture contamination rate peaked at 4.4% in
April 2020, coinciding with the surge of COVID19 patients [23]. Data on this particular region
are a strength for this study given that the
Detroit, Michigan area was one of the first
‘‘hotspots’’ within the United States.
This study must be interpreted in light of its
limitations. Notably, this is a retrospective
observational study, meaning that random
allocation was not done and selection bias can
exist between COVID-19 groups. Another limitation is the sample size. The number of
patients with true BSI and COVID-19 was low
overall, creating a small sample size for statistical analysis. This is especially true when compared to large studies with thousands of blood
cultures and COVID-19 patients [22, 41]. Small
sample sizes may have contributed to failure to
detect a difference between antibiotic consumption or other variables between contaminants and true BSI. In the methodology, groups
were separated by positive blood culture and
lack of positive blood culture, which grouped
patients with negative blood cultures (but collected and drawn) and no blood cultures together. Data were not collected on the proportion
of negative blood cultures compared with no
blood culture ordered. This selection could alter
the interpretation of the group without blood
cultures to have patients that do not meet any
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criteria for possible coinfection. Another limitation is that antibiotic data were not gathered
in the group without positive blood cultures
due to data reporting constraints. Without
antibiotic data on all COVID-19 cases (especially in those without positive blood cultures),
this contributes to the difficulty in detecting a
statistically significant effect. The study also
overlooks non-bloodstream infections, and
antibiotic use may be justified by other non-BSI
coinfections in either group. Lastly, two positive blood cultures were defined under true BSI
regardless of pathogen, and this may overestimate the amount of true BSI. Contamination
can sometimes occur where both blood culture
specimens are positive coincidentally. This definition was used given the difficulty in differentiating contamination between two blood
culture specimens versus true BSI, and in keeping with the Centers for Disease Control and
Prevention (CDC) National Healthcare Surveillance Network (NHSN) commonly accepted
algorithm for determining a contaminant [42].
Data from this study could help lead to recommendations to rely more closely on the
presence of certain neurological symptoms and/
or WBC, and less on the use of empirical
antibiotics when in the midst of a COVID-19
variant surge and questions of bacterial coinfection arise. However, more data that adhere to
robust study design are needed to appropriately
capture and interpret the full scope of clinical
evidence. Studies could be done using historical
controls that are able to distinguish whether
contamination and rates of bloodstream infection are higher or lower in a COVID-19 control
group. Many studies using this design found
higher levels of positive blood cultures and
higher contamination in COVID-19 patients,
ranging from 6.1 to 12.5% [16, 17, 19]. Studies
could also use prospective data or data linkage
that can offer important paths for future evidence. Some studies using these methods found
that BSI as a whole increased in the pandemic,
contamination rates increased with ICU bed
surges, and any BSI increased mortality
[18, 22, 43]. A large collection of patient data
using these study methods could construct a
laboratory algorithm model, similar to prediction models created for severe COVID-19 or

Infect Dis Ther (2022) 11:1281–1296

mortality, to better predict bacterial coinfection
in patients and ensure they are appropriately
treated [44–48]. This algorithm could then be
tested in a randomized controlled trial to overcome unmeasured confounders and evaluate
whether patients in the algorithm arm received
fewer antibiotics, with no increase in adverse
events, and with appropriate COVID-19 bacterial coinfection care without delay in comparison to the control arm.

CONCLUSIONS
In conclusion, this study provides some evidence that fever may be a poor marker for
coinfection among COVID-19 patients, and
that neurological symptoms and possibly
higher WBC may be a better marker for assessing bacterial BSI. True bloodstream coinfection
in this cohort led to worse overall mortality and
longer LOS in patients with COVID-19. Contamination rates from this study suggest that
about half of the positive blood cultures in
COVID-19 during the first month were contaminant blood cultures. There was high use of
antibiotics in both true BSI and contaminant
patients among those with positive blood cultures, but this analysis was limited by antibiotic
data collection and possible bacterial coinfections other than BSI. Further studies are warranted to fully remove potential confounding
factors and quantify independent associations
of BSI with neurological symptoms or WBC in
COVID-19, evaluate antibiotic use among negative or non-cultured patients, and illustrate
how bacterial coinfection rates or predictors
may change over time with different COVID-19
variants. Research should continue on clearly
identifying bacterial coinfection in order to
limit antimicrobial use among those not infected. This can prevent microbial resistance,
higher adverse effects, and increased patient
treatment costs by avoiding excess antibiotic
administration and can optimize future public
health.
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